Rx Medicare

AcelRx Pharmaceuticals, Inc. announced positive results from its first Phase 2 clinical study evaluating the functionality of the handheld device component of its ARX-01 Sufentanil NanoTab(TM) PCA System for management of acute post-operative pain in patients requiring opioid analgesia during hospitalization. Patients reliably self-administered sufentanil NanoTabs repeatedly over the 12-hour study without any ARX-01 System failures or dosing errors of any kind.

Read More…

Related Posts

• AcelRx Announces Successful Completion Of End-of-Phase 2 Meeting On ARX-01, Sufentanil NanoTab PCA System For Post-Operative Pain Management
• AcelRx Announces Positive Results From A Phase 2 Study Of ARX-03, A Sufentanil/Triazolam NanoTab For Procedural Sedation, Anxiolysis & Analgesia
• AcelRx Announces Positive Phase 2 Results From A Study Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
• Alkermes Announces Initiation Of Multidose Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation
• Spinal Restoration Initiates Patient Enrollment For Phase III Study Of Company’s Biostat(R) System
• Baxter Presents Clinical Efficacy Results From Phase III Study Of Seasonal Flu Vaccine
• Alkermes Announces Positive Results For Phase 1 Study Of New Drug Candidate For Treatment Of Opioid-Induced Constipation
• QRxPharma Initiates Second Pivotal Phase 3 Study Of MoxDuo(TM)IR Dual-Opioid(TM) For NDA Submission
• Phosphagenics Announces Positive Results From Phase 1B Study Of Transdermal Oxycodone Patch
• China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug
• QRxPharma Initiates Pivotal Phase 3 Study Of MoxDuo(TM)IR For Moderate To Severe Acute Pain
• Relationship of creative projects in anatomy to medical student professionalism, test performance and stress: an exploratory study
• Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 37 For The Treatment Of Opioid-Induced Constipation
• Pacira’s Phase III Study Of EXPAREL(TM) Meets Primary Pain Relief Endpoint
• Transdel Pharmaceuticals Announces Positive Phase 3 Study Results For Lead Topical Pain Drug Ketotransdel(R)

Tags: acelrx, component, handheld, nanotab, perfect, performance, phase, study, sufentanil

This entry was posted on Friday, July 24th, 2009 at 12:07 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.